ketamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1523	6740-88-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ketamine narketan (+/-)-Ketamine ketamine hydrochloride ketamine HCl	A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors. Molecular weight: 237.73 Formula: C13H16ClNO CLOGP: 2.93 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 29.10 ALOGS: -3.71 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ketamine
narketan
(+/-)-Ketamine
ketamine hydrochloride
ketamine HCl

A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.

Molecular weight: 237.73
Formula: C13H16ClNO
CLOGP: 2.93
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 29.10
ALOGS: -3.71
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	200 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	4 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	8.41 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	20 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	2.90 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	19 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.47 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.80 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 19, 1970	FDA	PAR STERILE PRODUCTS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	463.65	22.38	162	8655	19993	50576314
Dilatation intrahepatic duct acquired	143.38	22.38	31	8786	614	50595693
Bronchospasm	131.38	22.38	60	8757	14794	50581513
Propofol infusion syndrome	127.24	22.38	29	8788	737	50595570
Body tinea	126.05	22.38	32	8785	1295	50595012
Hydronephrosis	116.88	22.38	47	8770	8494	50587813
Inhibitory drug interaction	105.16	22.38	31	8786	2202	50594105
Infection susceptibility increased	104.95	22.38	32	8785	2552	50593755
Mitochondrial DNA mutation	102.65	22.38	20	8797	230	50596077
Drug ineffective for unapproved indication	102.63	22.38	57	8760	21224	50575083
Intra-abdominal pressure increased	99.06	22.38	19	8798	200	50596107
Pneumatosis	91.79	22.38	20	8797	411	50595896
Biliary dilatation	91.26	22.38	27	8790	1942	50594365
Glucose tolerance impaired	83.52	22.38	32	8785	5086	50591221
Sterile pyuria	82.14	22.38	12	8805	15	50596292
Impaired quality of life	81.73	22.38	33	8784	6023	50590284
Multiple-drug resistance	81.30	22.38	28	8789	3286	50593021
Delirium	80.98	22.38	61	8756	38131	50558176
Blood lactic acid increased	80.80	22.38	32	8785	5553	50590754
Hypercapnia	79.35	22.38	30	8787	4597	50591710
Respiratory depression	77.25	22.38	39	8778	11971	50584336
Oesophageal spasm	74.69	22.38	24	8793	2272	50594035
Necrosis ischaemic	74.57	22.38	19	8798	780	50595527
Blood pH decreased	73.11	22.38	24	8793	2431	50593876
Off label use	71.30	22.38	212	8605	474214	50122093
Status epilepticus	70.40	22.38	38	8779	13368	50582939
Drug ineffective	70.06	22.38	304	8513	819029	49777278
Oesophageal pain	70.00	22.38	24	8793	2778	50593529
Reduced bladder capacity	68.90	22.38	9	8808	0	50596307
Blood gases abnormal	68.61	22.38	17	8800	622	50595685
Intestinal ischaemia	68.36	22.38	30	8787	6727	50589580
Hypotension	67.33	22.38	135	8682	235334	50360973
Hyperaesthesia	65.97	22.38	31	8786	8142	50588165
Gene mutation	65.83	22.38	19	8798	1252	50595055
Unwanted awareness during anaesthesia	65.04	22.38	14	8803	271	50596036
Cardio-respiratory arrest	64.57	22.38	62	8755	53830	50542477
Cardiac arrest	64.30	22.38	76	8741	83575	50512732
Purpura	63.20	22.38	32	8785	9879	50586428
Drug abuse	62.72	22.38	64	8753	59782	50536525
Arthralgia	60.93	22.38	4	8813	438698	50157609
Intestinal infarction	60.86	22.38	17	8800	995	50595312
Bone density decreased	59.85	22.38	32	8785	11043	50585264
Anaphylactic reaction	58.82	22.38	59	8758	53996	50542311
Poor quality sleep	57.64	22.38	36	8781	16610	50579697
Bladder hypertrophy	57.06	22.38	12	8805	207	50596100
Venoocclusive liver disease	56.74	22.38	23	8794	4238	50592069
Impaired work ability	56.25	22.38	33	8784	13607	50582700
Shock	55.24	22.38	38	8779	20612	50575695
Local anaesthetic systemic toxicity	54.40	22.38	14	8803	598	50595709
Airway peak pressure increased	53.50	22.38	12	8805	283	50596024
Systemic inflammatory response syndrome	52.97	22.38	23	8794	5026	50591281
Respiratory acidosis	52.18	22.38	24	8793	6004	50590303
Contracted bladder	51.09	22.38	7	8810	3	50596304
Lung hyperinflation	50.37	22.38	15	8802	1103	50595204
PCO2 increased	50.04	22.38	15	8802	1128	50595179
Ultrasound ovary abnormal	47.61	22.38	9	8808	87	50596220
Anaphylactoid shock	47.26	22.38	11	8806	307	50596000
Hyperlipidaemia	46.34	22.38	32	8785	17458	50578849
Hepatocellular injury	45.36	22.38	37	8780	25910	50570397
Agitation	45.19	22.38	51	8766	53333	50542974
Perforation	43.71	22.38	13	8804	951	50595356
Oral herpes	43.67	22.38	33	8784	20692	50575615
PO2 decreased	43.14	22.38	14	8803	1367	50594940
Biliary tract disorder	42.90	22.38	12	8805	706	50595601
Lymphoedema	42.77	22.38	24	8793	9098	50587209
Sedation	42.01	22.38	38	8779	30572	50565735
Tonic clonic movements	40.52	22.38	13	8804	1224	50595083
Lower urinary tract symptoms	40.42	22.38	7	8810	39	50596268
Hepatotoxicity	39.75	22.38	35	8782	27191	50569116
Skin disorder	39.37	22.38	33	8784	23997	50572310
Ureteral polyp	38.28	22.38	5	8812	0	50596307
Cystitis ulcerative	38.28	22.38	5	8812	0	50596307
Metabolic acidosis	37.92	22.38	40	8777	38785	50557522
Blood bicarbonate decreased	37.28	22.38	15	8802	2710	50593597
Status asthmaticus	36.76	22.38	11	8806	822	50595485
Diastolic hypotension	35.73	22.38	7	8810	83	50596224
Renal infarct	35.34	22.38	12	8805	1348	50594959
Hallucination	35.17	22.38	42	8775	46615	50549692
Cystitis	35.05	22.38	41	8776	44523	50551784
Stress cardiomyopathy	34.95	22.38	20	8797	7867	50588440
Intensive care unit acquired weakness	34.24	22.38	10	8807	687	50595620
Reversible cerebral vasoconstriction syndrome	33.68	22.38	13	8804	2106	50594201
Headache	33.24	22.38	24	8793	506511	50089796
Tachycardia	33.07	22.38	61	8756	99702	50496605
Bladder necrosis	32.16	22.38	5	8812	12	50596295
Post procedural stroke	32.03	22.38	6	8811	55	50596252
Left ventricular hypertrophy	31.93	22.38	16	8801	4829	50591478
Cystitis interstitial	31.71	22.38	11	8806	1318	50594989
Ureteric stenosis	31.53	22.38	9	8808	570	50595737
Bladder disorder	30.44	22.38	18	8799	7525	50588782
Mucocutaneous haemorrhage	29.97	22.38	6	8811	80	50596227
Oxygen saturation decreased	29.76	22.38	49	8768	73199	50523108
Abdominal discomfort	29.64	22.38	3	8814	231638	50364669
Nausea	29.16	22.38	49	8768	705349	49890958
Blood creatine phosphokinase increased	29.06	22.38	29	8788	26338	50569969
Bradypnoea	29.01	22.38	13	8804	3061	50593246
Tachyphylaxis	28.22	22.38	7	8810	257	50596050
Cholestasis	28.11	22.38	28	8789	25373	50570934
Intensive care unit delirium	27.30	22.38	5	8812	40	50596267
Cyanosis	27.27	22.38	22	8795	15162	50581145
Haematuria	26.09	22.38	27	8790	25586	50570721
Sleep apnoea syndrome	25.84	22.38	26	8791	23842	50572465
Drug tolerance	25.82	22.38	14	8803	4962	50591345
Tinnitus	25.73	22.38	28	8789	28104	50568203
Urinary tract disorder	25.48	22.38	11	8806	2369	50593938
Immune thrombocytopenia	25.07	22.38	17	8800	9000	50587307
Alopecia	25.00	22.38	6	8811	245041	50351266
Rheumatoid arthritis	24.96	22.38	3	8814	202547	50393760
Euthyroid sick syndrome	24.82	22.38	5	8812	69	50596238
Cardiomegaly	24.28	22.38	21	8796	15924	50580383
Drug abuser	23.66	22.38	11	8806	2817	50593490
Peripheral swelling	23.16	22.38	4	8813	205932	50390375
Platelet disorder	23.02	22.38	9	8808	1508	50594799
Bladder neck obstruction	22.97	22.38	3	8814	0	50596307
Drug use disorder	22.79	22.38	11	8806	3061	50593246
Ureteral disorder	22.53	22.38	6	8811	293	50596014

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	334.15	21.71	126	7379	13210	29553812
Drug abuse	159.63	21.71	144	7361	79739	29487283
Cystitis ulcerative	131.05	21.71	18	7487	0	29567022
Drug ineffective	117.85	21.71	273	7232	362897	29204125
Hydronephrosis	92.84	21.71	45	7460	8685	29558337
Anaphylactic reaction	89.35	21.71	66	7439	27507	29539515
Hypotension	86.94	21.71	167	7338	194187	29372835
Sedation	80.79	21.71	52	7453	17353	29549669
Biopsy bladder abnormal	72.80	21.71	10	7495	0	29567022
Delirium	68.77	21.71	66	7439	39331	29527691
Bradycardia	65.65	21.71	82	7423	65547	29501475
Cystitis	65.58	21.71	35	7470	8257	29558765
Reduced bladder capacity	65.52	21.71	9	7496	0	29567022
Drug screen positive	63.97	21.71	27	7478	3774	29563248
Bronchospasm	63.43	21.71	36	7469	9573	29557449
Nightmare	62.79	21.71	38	7467	11379	29555643
Cystitis interstitial	62.05	21.71	13	7492	147	29566875
Respiratory depression	61.75	21.71	40	7465	13483	29553539
Off label use	56.81	21.71	186	7319	300614	29266408
Contracted bladder	51.32	21.71	8	7497	11	29567011
Pulseless electrical activity	50.43	21.71	27	7478	6407	29560615
Behaviour disorder	48.84	21.71	22	7483	3594	29563428
Toxicity to various agents	48.78	21.71	124	7381	173537	29393485
Diabetes insipidus	46.74	21.71	19	7486	2415	29564607
Cardiac arrest	46.25	21.71	80	7425	85511	29481511
Cholestasis	46.09	21.71	42	7463	23420	29543602
Drug dependence	42.08	21.71	38	7467	20943	29546079
Biliary dilatation	38.36	21.71	12	7493	711	29566311
Agitation	37.39	21.71	55	7450	51249	29515773
Diarrhoea	35.90	21.71	20	7485	332678	29234344
Accidental death	35.49	21.71	15	7490	2103	29564919
Drug ineffective for unapproved indication	35.10	21.71	29	7476	14185	29552837
Drug use disorder	34.45	21.71	17	7488	3405	29563617
Nephrolithiasis	34.25	21.71	37	7468	25297	29541725
Hyperaesthesia	34.23	21.71	17	7488	3452	29563570
Delayed recovery from anaesthesia	34.22	21.71	11	7494	712	29566310
Biliary tract disorder	33.48	21.71	11	7494	763	29566259
Tachycardia	33.13	21.71	63	7442	72347	29494675
Metabolic acidosis	32.82	21.71	44	7461	37618	29529404
Wolff-Parkinson-White syndrome	32.34	21.71	8	7497	197	29566825
Anaphylactoid shock	32.17	21.71	9	7496	361	29566661
Hyperammonaemia	31.51	21.71	19	7486	5644	29561378
Bladder disorder	31.50	21.71	15	7490	2779	29564243
Airway complication of anaesthesia	29.50	21.71	7	7498	144	29566878
Ureteral polyp	29.12	21.71	4	7501	0	29567022
Drug tolerance	28.76	21.71	13	7492	2140	29564882
Abdominal compartment syndrome	28.71	21.71	10	7495	829	29566193
Axillary pain	28.68	21.71	8	7497	317	29566705
Cholangiolitis	28.36	21.71	5	7500	20	29567002
Laryngospasm	28.00	21.71	11	7494	1279	29565743
Haematuria traumatic	27.93	21.71	7	7498	182	29566840
Brief psychotic disorder with marked stressors	27.65	21.71	7	7498	190	29566832
Fatigue	27.60	21.71	24	7481	316797	29250225
Neonatal hypoxia	27.39	21.71	8	7497	375	29566647
Urinary tract disorder	26.87	21.71	12	7493	1920	29565102
Multiple-drug resistance	26.78	21.71	15	7490	3885	29563137
Substance abuse	25.98	21.71	18	7487	6769	29560253
Dyspnoea	25.83	21.71	27	7478	326705	29240317
Pneumonia	25.83	21.71	26	7479	320146	29246876
Product use in unapproved indication	25.31	21.71	63	7442	86812	29480210
Hypoxia	25.18	21.71	44	7461	47335	29519687
Diastolic hypertension	24.70	21.71	5	7500	47	29566975
Hypercapnia	24.69	21.71	14	7491	3712	29563310
Sedation complication	24.59	21.71	10	7495	1272	29565750
Complication of device removal	24.42	21.71	5	7500	50	29566972
Anaesthetic complication neurological	24.17	21.71	7	7498	318	29566704
Intensive care unit acquired weakness	23.89	21.71	9	7496	934	29566088
Bladder hypertrophy	23.81	21.71	8	7497	595	29566427
Upper airway obstruction	23.64	21.71	8	7497	608	29566414
Transcranial electrical motor evoked potential monitoring abnormal	23.58	21.71	4	7501	12	29567010
Neutropenia	23.25	21.71	3	7502	131708	29435314
Somnolence	23.15	21.71	64	7441	93891	29473131
Unmasking of previously unidentified disease	22.39	21.71	8	7497	715	29566307
Muscle contracture	22.13	21.71	9	7496	1144	29565878

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	768.07	19.23	286	15508	30042	64452896
Hydronephrosis	210.27	19.23	91	15703	14034	64468904
Drug abuse	208.32	19.23	206	15588	132168	64350770
Bronchospasm	181.70	19.23	94	15700	21588	64461350
Drug ineffective	172.96	19.23	522	15272	839725	63643213
Cystitis ulcerative	168.26	19.23	23	15771	0	64482938
Hypotension	135.74	19.23	292	15502	380682	64102256
Anaphylactic reaction	134.96	19.23	121	15673	68543	64414395
Reduced bladder capacity	131.68	19.23	18	15776	0	64482938
Propofol infusion syndrome	131.32	19.23	37	15757	1580	64481358
Biliary dilatation	127.42	19.23	39	15755	2229	64480709
Drug ineffective for unapproved indication	120.59	19.23	82	15712	31051	64451887
Dilatation intrahepatic duct acquired	115.12	19.23	28	15766	666	64482272
Delirium	112.98	19.23	110	15684	69084	64413854
Body tinea	111.45	19.23	31	15763	1262	64481676
Off label use	110.25	19.23	372	15422	632434	63850504
Respiratory depression	108.44	19.23	69	15725	23374	64459564
Cardiac arrest	102.19	19.23	155	15639	153909	64329029
Mitochondrial DNA mutation	95.15	19.23	20	15774	239	64482699
Hypercapnia	93.43	19.23	43	15751	7651	64475287
Contracted bladder	92.72	19.23	14	15780	14	64482924
Intra-abdominal pressure increased	90.32	19.23	19	15775	228	64482710
Infection susceptibility increased	88.68	19.23	31	15763	2695	64480243
Hyperaesthesia	88.45	19.23	45	15749	9969	64472969
Arthralgia	88.26	19.23	5	15789	442255	64040683
Sedation	87.28	19.23	76	15718	41386	64441552
Sterile pyuria	86.01	19.23	15	15779	58	64482880
Cystitis	85.38	19.23	76	15718	42599	64440339
Cystitis interstitial	83.36	19.23	24	15770	1108	64481830
Pneumatosis	81.65	19.23	22	15772	794	64482144
Biopsy bladder abnormal	80.47	19.23	11	15783	0	64482938
Bladder hypertrophy	79.66	19.23	20	15774	544	64482394
Inhibitory drug interaction	76.51	19.23	30	15764	3597	64479341
Agitation	74.90	19.23	100	15694	88267	64394671
Multiple-drug resistance	74.79	19.23	35	15759	6467	64476471
Anaphylactoid shock	73.90	19.23	20	15774	734	64482204
Oesophageal spasm	71.85	19.23	26	15768	2499	64480439
Cholestasis	68.87	19.23	69	15725	44803	64438135
Cardio-respiratory arrest	68.03	19.23	101	15693	98292	64384646
Metabolic acidosis	65.88	19.23	84	15710	70874	64412064
Ureteral polyp	65.84	19.23	9	15785	0	64482938
Impaired quality of life	65.79	19.23	32	15762	6439	64476499
Oesophageal pain	65.36	19.23	26	15768	3237	64479701
Blood lactic acid increased	64.60	19.23	37	15757	10364	64472574
Necrosis ischaemic	64.26	19.23	19	15775	964	64481974
Respiratory acidosis	63.74	19.23	36	15758	9819	64473119
Diabetes insipidus	63.58	19.23	28	15766	4493	64478445
Bladder disorder	63.10	19.23	33	15761	7734	64475204
Glucose tolerance impaired	62.92	19.23	31	15763	6412	64476526
Drug screen positive	60.26	19.23	29	15765	5700	64477238
Tachycardia	59.25	19.23	120	15674	149459	64333479
Shock	59.04	19.23	59	15735	38181	64444757
Status epilepticus	58.72	19.23	46	15748	21617	64461321
Laryngospasm	57.22	19.23	24	15770	3421	64479517
Headache	56.06	19.23	30	15764	529437	63953501
Intestinal ischaemia	55.91	19.23	35	15759	11514	64471424
Drug dependence	54.41	19.23	53	15741	33259	64449679
Lower urinary tract symptoms	53.95	19.23	12	15782	190	64482748
Intensive care unit acquired weakness	53.73	19.23	19	15775	1708	64481230
Airway peak pressure increased	52.86	19.23	13	15781	324	64482614
Diarrhoea	51.43	19.23	61	15733	722643	63760295
Blood gases abnormal	51.40	19.23	16	15778	967	64481971
Intestinal infarction	51.07	19.23	17	15777	1274	64481664
Hepatocellular injury	50.84	19.23	59	15735	45176	64437762
Bradycardia	50.61	19.23	98	15696	118121	64364817
Bone density decreased	50.30	19.23	31	15763	9921	64473017
Gene mutation	50.27	19.23	19	15775	2063	64480875
Biliary tract disorder	49.80	19.23	17	15777	1376	64481562
Urinary tract disorder	49.07	19.23	21	15773	3145	64479793
Local anaesthetic systemic toxicity	48.12	19.23	14	15780	671	64482267
Drug use disorder	47.13	19.23	25	15769	6029	64476909
Poor quality sleep	46.58	19.23	38	15756	18913	64464025
Behaviour disorder	45.16	19.23	22	15772	4440	64478498
Unwanted awareness during anaesthesia	44.74	19.23	11	15783	274	64482664
Ultrasound ovary abnormal	44.56	19.23	9	15785	87	64482851
Lung hyperinflation	43.64	19.23	16	15778	1596	64481342
Status asthmaticus	43.34	19.23	14	15780	954	64481984
Blood pH decreased	42.45	19.23	21	15773	4381	64478557
Joint swelling	41.22	19.23	3	15791	215379	64267559
Dyspnoea	40.89	19.23	71	15723	718603	63764335
Airway complication of anaesthesia	40.71	19.23	11	15783	401	64482537
Impaired work ability	40.56	19.23	32	15762	15187	64467751
Ureteric stenosis	39.66	19.23	14	15780	1252	64481686
PCO2 increased	39.48	19.23	15	15779	1652	64481286
Pulseless electrical activity	38.80	19.23	29	15765	12710	64470228
Drug tolerance	38.73	19.23	22	15772	6063	64476875
Ureteral disorder	38.50	19.23	11	15783	494	64482444
Lymphoedema	38.12	19.23	26	15768	9879	64473059
Hypoxia	37.62	19.23	73	15721	88076	64394862
Nightmare	37.31	19.23	35	15759	20958	64461980
Perforation	37.13	19.23	13	15781	1135	64481803
Tonic clonic movements	36.91	19.23	15	15779	1974	64480964
Hallucination	35.71	19.23	64	15730	72724	64410214
Venoocclusive liver disease	35.51	19.23	25	15769	9990	64472948
Purpura	35.04	19.23	31	15763	17215	64465723
Sedation complication	34.76	19.23	25	15769	10329	64472609
Drug abuser	34.30	19.23	20	15774	5788	64477150
Accidental death	33.65	19.23	17	15777	3708	64479230
Delayed recovery from anaesthesia	33.50	19.23	13	15781	1515	64481423
Anaesthetic complication neurological	33.30	19.23	10	15784	535	64482403
Systemic inflammatory response syndrome	32.74	19.23	24	15770	10211	64472727
Asthenia	32.70	19.23	34	15760	428010	64054928
Stress cardiomyopathy	32.57	19.23	23	15771	9234	64473704
Hepatotoxicity	31.97	19.23	44	15750	39918	64443020
Nasopharyngitis	31.76	19.23	5	15789	196068	64286870
Product use in unapproved indication	31.50	19.23	105	15689	176513	64306425
Dissociative disorder	31.33	19.23	9	15785	412	64482526
Abdominal discomfort	31.05	19.23	4	15790	182318	64300620
Wolff-Parkinson-White syndrome	30.61	19.23	8	15786	256	64482682
Oral herpes	30.24	19.23	32	15762	22120	64460818
Diastolic hypotension	30.12	19.23	7	15787	136	64482802
Fall	29.75	19.23	35	15759	416791	64066147
Transcranial electrical motor evoked potential monitoring abnormal	29.40	19.23	5	15789	16	64482922
PO2 decreased	29.34	19.23	14	15780	2699	64480239
Neutropenia	29.33	19.23	11	15783	239613	64243325
Bladder necrosis	29.17	19.23	5	15789	17	64482921
Type I hypersensitivity	28.50	19.23	15	15779	3559	64479379
Peripheral swelling	28.42	19.23	8	15786	209145	64273793
Circulatory collapse	28.28	19.23	38	15756	33694	64449244
Back pain	28.18	19.23	13	15781	250158	64232780
Haematuria traumatic	28.14	19.23	7	15787	183	64482755
Cough	27.92	19.23	20	15774	302128	64180810
Cholangiolitis	27.62	19.23	5	15789	25	64482913
Hyperlipidaemia	27.55	19.23	31	15763	22945	64459993
Sleep apnoea syndrome	27.17	19.23	35	15759	29797	64453141
Chest pain	26.99	19.23	12	15782	235968	64246970
Oedema peripheral	26.86	19.23	9	15785	210308	64272630
Pyuria	26.69	19.23	12	15782	2021	64480917
Macroglossia	26.67	19.23	10	15784	1062	64481876
Dehydration	26.45	19.23	10	15784	216753	64266185
Post procedural stroke	26.30	19.23	6	15788	107	64482831
Swelling	26.14	19.23	4	15790	160214	64322724
Oxygen saturation decreased	25.97	19.23	71	15723	107105	64375833
Paralysis	25.90	19.23	22	15772	11573	64471365
Brief psychotic disorder with marked stressors	25.68	19.23	7	15787	264	64482674
Pain in extremity	25.55	19.23	22	15772	303063	64179875
Miosis	25.28	19.23	23	15771	13243	64469695
Alopecia	25.15	19.23	5	15789	165685	64317253
Upper airway obstruction	25.11	19.23	10	15784	1248	64481690
Intensive care unit delirium	25.07	19.23	5	15789	45	64482893
Reversible cerebral vasoconstriction syndrome	25.07	19.23	12	15782	2330	64480608
Renal infarct	24.74	19.23	12	15782	2399	64480539
Skin disorder	24.46	19.23	32	15762	27648	64455290
Blood bicarbonate decreased	24.30	19.23	15	15779	4814	64478124
Decreased appetite	24.22	19.23	20	15774	281269	64201669
Drug intolerance	24.08	19.23	8	15786	187984	64294954
Neuromuscular block prolonged	23.89	19.23	9	15785	968	64481970
Abdominal compartment syndrome	23.89	19.23	10	15784	1418	64481520
Euthyroid sick syndrome	23.84	19.23	5	15789	59	64482879
Apnoea	23.74	19.23	20	15774	10402	64472536
Product dose omission issue	23.73	19.23	9	15785	194738	64288200
Fatigue	23.56	19.23	99	15695	748631	63734307
Mucocutaneous haemorrhage	23.43	19.23	6	15788	177	64482761
Bradypnoea	23.38	19.23	15	15779	5144	64477794
Diastolic hypertension	22.73	19.23	5	15789	75	64482863
Hyperammonaemia	22.55	19.23	19	15775	9885	64473053
Tinnitus	22.09	19.23	34	15760	34099	64448839
Symptom masked	22.07	19.23	9	15785	1195	64481743
Anaemia	21.83	19.23	37	15757	378643	64104295
Cyanosis	21.77	19.23	27	15767	22128	64460810
Urogenital fistula	21.67	19.23	5	15789	94	64482844
Liver function test abnormal	21.54	19.23	46	15748	59355	64423583
Substance abuse	21.51	19.23	18	15776	9274	64473664
Pain	21.48	19.23	67	15727	553444	63929494
Weight decreased	21.45	19.23	23	15771	285716	64197222
Mania	21.30	19.23	23	15771	16263	64466675
Aplastic anaemia	20.60	19.23	21	15773	13899	64469039
Muscle contracture	19.99	19.23	10	15784	2135	64480803
Haematuria	19.86	19.23	45	15749	60426	64422512
Arthropathy	19.77	19.23	3	15791	120964	64361974
Anterograde amnesia	19.75	19.23	7	15787	633	64482305
Pneumonia	19.48	19.23	71	15723	559505	63923433
Haemodynamic instability	19.40	19.23	21	15773	14891	64468047
Infusion related reaction	19.38	19.23	8	15786	164459	64318479
Cystitis noninfective	19.36	19.23	8	15786	1098	64481840
Urinary tract infection	19.28	19.23	17	15777	231579	64251359

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N01AX03	NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Other general anesthetics
MeSH PA	D000700	Analgesics
MeSH PA	D000777	Anesthetics
MeSH PA	D000778	Anesthetics, Dissociative
MeSH PA	D018686	Anesthetics, Intravenous
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D018691	Excitatory Amino Acid Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:38877	intravenous anesthetics
CHEBI has role	CHEBI:50910	agente neurotoxico
CHEBI has role	CHEBI:60643	N-methyl-D-aspartate receptor antagonists
CHEBI has role	CHEBI:78298	environmental contaminants
FDA EPC	N0000175681	General Anesthetic
FDA PE	N0000175975	General Anesthesia

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
General anesthesia	indication	50697003
Local anesthesia	indication	386761002
Pain	off-label use	22253000
Inflammatory disease of mucous membrane	off-label use	95361005
Major depressive disorder	off-label use	370143000
Delirium	contraindication	2776000
Ocular hypertension	contraindication	4210003	DOID:9282
Alcoholism	contraindication	7200002
Myocardial infarction	contraindication	22298006	DOID:5844
Alcohol intoxication	contraindication	25702006
Hypertensive disorder	contraindication	38341003	DOID:10763
Decreased respiratory function	contraindication	80954004
Thyrotoxicosis	contraindication	90739004	DOID:7997
Acute disease of cardiovascular system	contraindication	128487001
Decompensated cardiac failure	contraindication	195111005
Cerebrovascular accident	contraindication	230690007
Raised intracranial pressure	contraindication	271719001	DOID:9428
Cerebral trauma	contraindication	275382005
Impaired cognition	contraindication	386806002
Myocardial ischemia	contraindication	414795007	DOID:3393
Hypertensive urgency	contraindication	443482000
Psychiatric Disturbance	contraindication
Cardiac Decompensation	contraindication

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Restraint	Indication
Cats	Anesthesia in diagnostic or minor surgical procedures that do not require skeletal muscle relaxation	Indication
Primates	Restraint	Indication
Primates	Anesthesia in diagnostic or minor surgical procedures that do not require skeletal muscle relaxation	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Ketaset	Zoetis Inc.	1
Ketaset, Vetalar	Boehringer lngelheim Animal Health USA Inc.	1
Ketaset Plus	Zoetis Inc.	3
Ketamine Hydrochloride Injection	Cronus Pharma Specialities India Private Limited	1
Ketamine Hydrochloride Injection, USP	Elanco US Inc.	1
VetaKet	Akorn Animal Health Inc.	1
Ketamine Hydrochloride Injection, USP	Dechra Veterinary Products LLC	1
Ketamine HCL	Mylan Institutional LLC, a Viatris Company	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.65	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Glutamate [NMDA] receptor	Ion channel	O15399 O60391 Q05586 Q12879 Q13224 Q14957 Q8TCU5	NMDE4_HUMAN NMD3B_HUMAN NMDZ1_HUMAN NMDE1_HUMAN NMDE2_HUMAN NMDE3_HUMAN NMD3A_HUMAN	BLOCKER	Ki	6.38	CHEMBL	CHEMBL
Glutamate receptor ionotropic AMPA	Ion channel	P42261 P42262 P42263 P48058	GRIA1_HUMAN GRIA2_HUMAN GRIA3_HUMAN GRIA4_HUMAN	OPENER			SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Acetylcholine receptor subunit alpha	Ion channel		ACHA_TORCA		IC50	5.31	CHEMBL
Glutamate NMDA receptor	Ion channel		NMDZ1_RAT NMDE1_RAT NMDE2_RAT NMDE3_RAT NMDE4_RAT NMD3B_RAT NMD3A_RAT		IC50	6.21	CHEMBL

External reference:

ID	Source
4019796	VUID
N0000147885	NUI
D00711	KEGG_DRUG
1867-66-9	SECONDARY_CAS_RN
4018154	VANDF
4019796	VANDF
C0022614	UMLSCUI
CHEBI:6121	CHEBI
CHEMBL742	ChEMBL_ID
DB01221	DRUGBANK_ID
CHEMBL1714	ChEMBL_ID
D007649	MESH_DESCRIPTOR_UI
3821	PUBCHEM_CID
4233	IUPHAR_LIGAND_ID
2156	INN_ID
690G0D6V8H	UNII
203184	RXNORM
4944	MMSL
9883	MMSL
d00272	MMSL
001403	NDDF
004581	NDDF
31706007	SNOMEDCT_US
333847008	SNOMEDCT_US
373464007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9508	INJECTION	50 mg	INTRAMUSCULAR	ANDA	27 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9509	INJECTION	100 mg	INTRAMUSCULAR	ANDA	27 sections
KETALAR	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9880	INJECTION	10 mg	INTRAVENOUS	NDA	17 sections
KETAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9881	INJECTION, SOLUTION, CONCENTRATE	100 mg	INTRAMUSCULAR	ANDA	19 sections
KETAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9882	INJECTION, SOLUTION, CONCENTRATE	50 mg	INTRAMUSCULAR	ANDA	14 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2051	INJECTION, SOLUTION, CONCENTRATE	100 mg	INTRAMUSCULAR	ANDA	31 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2053	INJECTION, SOLUTION, CONCENTRATE	50 mg	INTRAMUSCULAR	ANDA	31 sections
Ketalar	HUMAN PRESCRIPTION DRUG LABEL	1	42023-113	INJECTION	10 mg	INTRAMUSCULAR	NDA	27 sections
Ketalar	HUMAN PRESCRIPTION DRUG LABEL	1	42023-113	INJECTION	10 mg	INTRAMUSCULAR	NDA	27 sections
Ketalar	HUMAN PRESCRIPTION DRUG LABEL	1	42023-114	INJECTION	50 mg	INTRAMUSCULAR	NDA	27 sections
Ketalar	HUMAN PRESCRIPTION DRUG LABEL	1	42023-114	INJECTION	50 mg	INTRAMUSCULAR	NDA	27 sections
Ketalar	HUMAN PRESCRIPTION DRUG LABEL	1	42023-115	INJECTION	100 mg	INTRAMUSCULAR	NDA	27 sections
Ketalar	HUMAN PRESCRIPTION DRUG LABEL	1	42023-115	INJECTION	100 mg	INTRAMUSCULAR	NDA	27 sections
KETALAR	HUMAN PRESCRIPTION DRUG LABEL	1	52584-037	INJECTION	10 mg	INTRAVENOUS	NDA	19 sections
KETAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-038	INJECTION, SOLUTION, CONCENTRATE	50 mg	INTRAMUSCULAR	ANDA	14 sections
KETAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-040	INJECTION, SOLUTION, CONCENTRATE	100 mg	INTRAMUSCULAR	ANDA	19 sections
KETAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-108	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	14 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4399	INJECTION, SOLUTION, CONCENTRATE	50 mg	INTRAMUSCULAR	ANDA	19 sections
KETAMINE HYDROCHLORIDE	Human Prescription Drug Label	1	55150-438	INJECTION	10 mg	INTRAVENOUS	ANDA	14 sections
KETAMINE HYDROCHLORIDE	Human Prescription Drug Label	1	55150-439	INJECTION	50 mg	INTRAVENOUS	ANDA	14 sections
KETAMINE HYDROCHLORIDE	Human Prescription Drug Label	1	55150-440	INJECTION	100 mg	INTRAVENOUS	ANDA	14 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	67457-001	INJECTION, SOLUTION	50 mg	INTRAVENOUS	ANDA	22 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	67457-108	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	22 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	67457-181	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	22 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2787	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	22 sections
MKO Melt Dose Pack	HUMAN PRESCRIPTION DRUG LABEL	3	71384-410	TROCHE	25 mg	SUBLINGUAL	unapproved drug other	2 sections
MKH Dose Pack	HUMAN PRESCRIPTION DRUG LABEL	3	71384-420	TROCHE	25 mg	SUBLINGUAL	unapproved drug other	2 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	71872-7258	INJECTION	100 mg	INTRAMUSCULAR	ANDA	27 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	72572-320	INJECTION	50 mg	INTRAMUSCULAR	ANDA	27 sections
Ketamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	72572-321	INJECTION	100 mg	INTRAMUSCULAR	ANDA	27 sections